TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
CRISPR-Cas Systems
Codon, Nonsense
Eukaryotic Initiation Factor-4E
/ metabolism
Gene Editing
Germ-Line Mutation
Humans
Induced Pluripotent Stem Cells
/ cytology
Intracellular Signaling Peptides and Proteins
/ metabolism
Mechanistic Target of Rapamycin Complex 1
/ antagonists & inhibitors
Neural Stem Cells
/ metabolism
Neurogenesis
Phenotype
Protein Serine-Threonine Kinases
/ metabolism
RNA-Seq
Signal Transduction
Sirolimus
Tuberous Sclerosis
Tuberous Sclerosis Complex 1 Protein
/ genetics
CRISPR/Cas9
Disease modeling
Early neurodevelopment
Induced pluripotent stem cells
MEK-ERK1/2
MNK1/2-eIF4E
Neural progenitor cells
TSC1
Tuberous sclerosis complex
mTORC1
Journal
Molecular autism
ISSN: 2040-2392
Titre abrégé: Mol Autism
Pays: England
ID NLM: 101534222
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
08
2019
accepted:
29
12
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
1
1
2021
Statut:
epublish
Résumé
Tuberous sclerosis complex (TSC) is a neurodevelopmental disorder with frequent occurrence of epilepsy, autism spectrum disorder (ASD), intellectual disability (ID), and tumors in multiple organs. The aberrant activation of mTORC1 in TSC has led to treatment with mTORC1 inhibitor rapamycin as a lifelong therapy for tumors, but TSC-associated neurocognitive manifestations remain unaffected by rapamycin. Here, we generated patient-specific, induced pluripotent stem cells (iPSCs) from a TSC patient with a heterozygous, germline, nonsense mutation in exon 15 of Differentiated NPCs revealed enlarged cell size in TSC1-Het and Null NPCs, consistent with mTORC1 activation. TSC1-Het and Null NPCs also revealed enhanced proliferation and altered neurite outgrowth in a genotype-dependent manner, which was not reversed by rapamycin. Transcriptome analyses of TSC1-NPCs revealed differentially expressed genes that display a genotype-dependent linear response, i.e., genes upregulated/downregulated in Het were further increased/decreased in Null. In particular, genes linked to ASD, epilepsy, and ID were significantly upregulated or downregulated warranting further investigation. In TSC1-Het and Null NPCs, we also observed basal activation of ERK1/2, which was further activated upon rapamycin treatment. Rapamycin also increased MNK1/2-eIF4E signaling in TSC1-deficient NPCs. MEK-ERK and MNK-eIF4E pathways regulate protein translation, and our results suggest that aberrant translation distinct in TSC1/2-deficient NPCs could play a role in neurodevelopmental defects. Our data showing upregulation of these signaling pathways by rapamycin support a strategy to combine a MEK or a MNK inhibitor with rapamycin that may be superior for TSC-associated CNS defects. Importantly, our generation of isogenic sets of NPCs from TSC patients provides a valuable platform for translatome and large-scale drug screening studies. Overall, our studies further support the notion that early developmental events such as NPC proliferation and initial process formation, such as neurite number and length that occur prior to neuronal differentiation, represent primary events in neurogenesis critical to disease pathogenesis of neurodevelopmental disorders such as ASD.
Sections du résumé
Background
Tuberous sclerosis complex (TSC) is a neurodevelopmental disorder with frequent occurrence of epilepsy, autism spectrum disorder (ASD), intellectual disability (ID), and tumors in multiple organs. The aberrant activation of mTORC1 in TSC has led to treatment with mTORC1 inhibitor rapamycin as a lifelong therapy for tumors, but TSC-associated neurocognitive manifestations remain unaffected by rapamycin.
Methods
Here, we generated patient-specific, induced pluripotent stem cells (iPSCs) from a TSC patient with a heterozygous, germline, nonsense mutation in exon 15 of
Results
Differentiated NPCs revealed enlarged cell size in TSC1-Het and Null NPCs, consistent with mTORC1 activation. TSC1-Het and Null NPCs also revealed enhanced proliferation and altered neurite outgrowth in a genotype-dependent manner, which was not reversed by rapamycin. Transcriptome analyses of TSC1-NPCs revealed differentially expressed genes that display a genotype-dependent linear response, i.e., genes upregulated/downregulated in Het were further increased/decreased in Null. In particular, genes linked to ASD, epilepsy, and ID were significantly upregulated or downregulated warranting further investigation. In TSC1-Het and Null NPCs, we also observed basal activation of ERK1/2, which was further activated upon rapamycin treatment. Rapamycin also increased MNK1/2-eIF4E signaling in TSC1-deficient NPCs.
Conclusion
MEK-ERK and MNK-eIF4E pathways regulate protein translation, and our results suggest that aberrant translation distinct in TSC1/2-deficient NPCs could play a role in neurodevelopmental defects. Our data showing upregulation of these signaling pathways by rapamycin support a strategy to combine a MEK or a MNK inhibitor with rapamycin that may be superior for TSC-associated CNS defects. Importantly, our generation of isogenic sets of NPCs from TSC patients provides a valuable platform for translatome and large-scale drug screening studies. Overall, our studies further support the notion that early developmental events such as NPC proliferation and initial process formation, such as neurite number and length that occur prior to neuronal differentiation, represent primary events in neurogenesis critical to disease pathogenesis of neurodevelopmental disorders such as ASD.
Identifiants
pubmed: 31921404
doi: 10.1186/s13229-019-0311-3
pii: 311
pmc: PMC6945400
doi:
Substances chimiques
Codon, Nonsense
0
Eukaryotic Initiation Factor-4E
0
Intracellular Signaling Peptides and Proteins
0
TSC1 protein, human
0
Tuberous Sclerosis Complex 1 Protein
0
MKNK1 protein, human
EC 2.7.1.-
Mechanistic Target of Rapamycin Complex 1
EC 2.7.11.1
Protein Serine-Threonine Kinases
EC 2.7.11.1
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Subventions
Organisme : NINDS NIH HHS
ID : R01 NS109540
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s). 2020.
Déclaration de conflit d'intérêts
Competing interestsSJH is a member of the scientific advisory boards of Frequency Therapeutics, Psy Therapeutics, and Souvien Therapeutics, none of who were involved in this study. SDS is a scientific advisor for Outermost Therapeutics, Inc., which played no part in the present study. The other authors declare no competing interests.
Références
Mol Cell Probes. 2018 Aug;40:52-59
pubmed: 29307697
Bioinformatics. 2012 Jun 1;28(11):1530-2
pubmed: 22539670
Trends Biochem Sci. 2016 Oct;41(10):847-858
pubmed: 27527252
Nat Commun. 2018 May 15;9(1):1925
pubmed: 29765017
PLoS One. 2011;6(10):e26203
pubmed: 22022567
Appl Clin Genet. 2016 Dec 21;10:1-8
pubmed: 28053551
Cell Death Discov. 2017 Nov 13;3:17071
pubmed: 29152378
Bioinformatics. 2012 Aug 15;28(16):2184-5
pubmed: 22743226
Stem Cell Reports. 2017 Apr 11;8(4):883-893
pubmed: 28344003
Am J Hum Genet. 2014 May 1;94(5):677-94
pubmed: 24768552
Ann N Y Acad Sci. 2019 Mar 15;:null
pubmed: 30875083
Epilepsia. 2018 Mar;59(3):679-689
pubmed: 29377098
Science. 2011 Jun 10;332(6035):1322-6
pubmed: 21659605
Hum Mol Genet. 2012 Sep 1;21(17):3795-805
pubmed: 22641815
J Neurosci. 2019 Nov 20;39(47):9294-9305
pubmed: 31591157
Mol Cell Biol. 2007 Nov;27(21):7405-13
pubmed: 17724079
Front Cell Dev Biol. 2014 Nov 25;2:69
pubmed: 25505789
Front Chem. 2016 Mar 15;4:12
pubmed: 27014681
FEBS Lett. 2011 Apr 6;585(7):973-80
pubmed: 21329690
Cancer Res. 2005 Aug 15;65(16):7052-8
pubmed: 16103051
Nat Commun. 2015 Mar 10;6:6404
pubmed: 25752243
Dis Markers. 2015;2015:724935
pubmed: 26819491
Cell Tissue Res. 2018 Jan;371(1):143-151
pubmed: 29079884
Cell Rep. 2016 Apr 5;15(1):86-95
pubmed: 27052171
Nat Neurosci. 2019 Mar;22(3):374-385
pubmed: 30718903
Nat Protoc. 2013 Mar;8(3):568-82
pubmed: 23429718
Am J Hum Genet. 2014 Jun 5;94(6):870-83
pubmed: 24906019
Nat Med. 2018 Oct;24(10):1568-1578
pubmed: 30127391
Stem Cell Reports. 2019 Jan 8;12(1):42-56
pubmed: 30581017
Transl Psychiatry. 2015 May 19;5:e568
pubmed: 25989142
Neurosci Biobehav Rev. 2016 May;64:185-95
pubmed: 26949225
J Med Genet. 2019 Feb;56(2):81-88
pubmed: 30287595
Dis Model Mech. 2013 Jul;6(4):896-904
pubmed: 23751357
Nat Biotechnol. 2015 Jan;33(1):58-63
pubmed: 25437882
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Hum Mutat. 1999;14(5):412-22
pubmed: 10533067
Cell. 2004 Feb 6;116(3):467-79
pubmed: 15016380
J Vis Exp. 2018 Mar 2;(133):
pubmed: 29553565
Mol Cytogenet. 2014 Dec 31;7(1):97
pubmed: 25606055
Nature. 2014 Nov 13;515(7526):209-15
pubmed: 25363760
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cell. 2008 Sep 19;134(6):1042-54
pubmed: 18805096
Pediatr Neurol. 2016 Jul;60:1-12
pubmed: 27267556
Cell Stem Cell. 2010 Nov 5;7(5):618-30
pubmed: 20888316
Genome Res. 2011 Sep;21(9):1543-51
pubmed: 21816910
Nat Rev Dis Primers. 2016 May 26;2:16035
pubmed: 27226234
FEBS Lett. 2013 Aug 19;587(16):2623-8
pubmed: 23831578
Med Sci Monit Basic Res. 2015 Nov 26;21:241-6
pubmed: 26609771
Biochem J. 2008 Jun 1;412(2):179-90
pubmed: 18466115
Pediatr Neurol. 2014 Apr;50(4):290-6
pubmed: 24486221
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4468-77
pubmed: 25294932
Science. 2008 Jul 11;321(5886):218-23
pubmed: 18621663
Stem Cells. 2018 Feb;36(2):146-160
pubmed: 29178352
Mol Psychiatry. 2018 Nov;23(11):2167-2183
pubmed: 29449635
Mol Psychiatry. 2015 Mar;20(3):361-8
pubmed: 24686136
Cancer Res. 2004 Feb 1;64(3):812-6
pubmed: 14871804
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
J Biol Chem. 2012 Aug 31;287(36):30063-72
pubmed: 22798074
J Neurodev Disord. 2015;7(1):26
pubmed: 26257835
Annu Rev Genomics Hum Genet. 2019 Aug 31;20:217-240
pubmed: 31018109
Ann Clin Transl Neurol. 2017 Nov 12;4(12):877-887
pubmed: 29296616
Nat Neurosci. 2016 Mar;19(3):517-22
pubmed: 26829649
Mol Psychiatry. 2017 Jun;22(6):820-835
pubmed: 27378147
Mol Cell Biol. 2009 Aug;29(15):4250-61
pubmed: 19451225
Clin Cancer Res. 2011 Jun 15;17(12):4071-81
pubmed: 21525172
N Engl J Med. 2008 Jan 10;358(2):140-51
pubmed: 18184959
Mol Autism. 2014 Apr 10;5(1):28
pubmed: 24720851
Cell Stem Cell. 2013 Mar 7;12(3):354-67
pubmed: 23472874
Autism Res Treat. 2014;2014:242048
pubmed: 24672722
Cell. 2008 Oct 31;135(3):401-6
pubmed: 18984149
N Engl J Med. 2010 Nov 4;363(19):1801-11
pubmed: 21047224
Mol Psychiatry. 2019 Feb;24(2):241-251
pubmed: 29892053
J Neurosci. 2015 Jan 21;35(3):972-84
pubmed: 25609615
Mol Psychiatry. 2018 Apr;23(4):1051-1065
pubmed: 28439102